1Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R,Hotz-Behoftsitz C, Palizbau A, Pombo J, Watts J, Morham SG, Bjarnason J. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002; 122:1913-1923.
2De Vos M, Cuvelier C.Mielanths H. Ileocolonoscopy in seronegative spondylarthopathy. Gastroenterology 1989; 96:339-344.
3Leirisolo-Repo H, Turunen U, Stenman S. High frequency of silent inflammatory bowel disease in spondylarthropathy.Arthritis Rheum 1994; 37:23-31.
4Smale S, Natt RS, Orchard TR, Russell AS, Bjarnason I. Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum 2001; 44:2728-2736.
5Laine L, Connors LG, Reicin A, Howkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.Gastroenterology 2003; 124:288-292.
6Vane JR. Inhib-ition of prostaglandin synthesis as a mechanism of action of aspirin - like drugs. Nature 1971; 231:232-235.
7Mahmud T, Rafi SS, Scott DL, Wrigglesworth JM, Bjarnason I. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum 1996; 39:1998-2003.
8Brune K, Schweitzer A, Eckert A. Parietal cells of the stomach trap salicylates during absorption. Biochem Pharmacol 1977;26:1735-1740.
9Lichtenberger LM, Wang ZM, Romero JJ, Ulloa C, Perez JC,Giraud MN, Barreto JC. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids:Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1995; 1:154-158.
10Giraud MN, Motta C, Romero JJ, Lichtenberger LM. Interaction of indomethacin and naproxen with gastric surface-active phospholipids: a possible mechanism from the gastric toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs).Biochem Pharmacol 1999; 57:247-254.
6Rostom A, Moayyedi P, Hunt R.Systematic Review: Canadian Consensus guidelines on long-term NSAID therapy and the need for gastroprotection.Aliment Pharmacol Ther 2008 Nov 26.[Epub ahead of print]
7Wallace JL, Vong L.NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs.Curr Opin Investig Drugs 2008; 9: 1151-1156
8Roughead EE, Ramsay E, Pratt N, Gilbert AL.NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans.Drug Saf 2008; 31: 997-1003
